Febuxostat-Controlled, Double-Blind, Comparative Study of FYU-981 for Hyperuricemia With or Without Gout to Evaluate the Safety and Noninferiority of FYU-981 (Phase III Study)
Latest Information Update: 22 Nov 2021
At a glance
- Drugs Dotinurad (Primary) ; Febuxostat
- Indications Hyperuricaemia
- Focus Registrational; Therapeutic Use
- Sponsors Mochida Pharmaceutical
- 15 Nov 2021 Results of systematic review and meta-analysis of randomized controlled trials (NCT02416167, NCT03100318, NCT03372200 ) were published in the International Journal of Clinical Pharmacology and Therapeutics.
- 21 Sep 2018 Status changed from recruiting to completed.
- 23 Jan 2018 Status changed from not yet recruiting to recruiting.